Alimera Sciences, Inc.

NasdaqGM:ALIM Stock Report

Market Cap: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences Dividends and Buybacks

Dividend criteria checks 0/6

Alimera Sciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.03%

Buyback Yield

Total Shareholder Yield-0.03%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Sep 11

Alimera Sciences: Cheap CVR Optionality

Jul 16

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Jun 18
Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Feb 15
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Dec 30
Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Oct 13
Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Sep 13
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06
Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24
Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11
Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ALIM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALIM's dividend payments have been increasing.


Dividend Yield vs Market

Alimera Sciences Dividend Yield vs Market
How does ALIM dividend yield compare to the market?
SegmentDividend Yield
Company (ALIM)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast (ALIM) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ALIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALIM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ALIM's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALIM has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/18 04:16
End of Day Share Price 2024/09/13 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alimera Sciences, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.